| Reuters (Reuters) – Merck & Co Inc said it would buy Idenix Pharmaceuticals Inc in a deal valued at about $3.85 billion to complement its hepatitis C portfolio. Merck said it would pay $24.50 per share – more than three times Idenix’s Friday closing price of $7.23. Merck to Acquire IdenixMarketWatch Merck to Acquire Idenix PharmaceuticalsNew York Times Why Merck Just Spent $4 Billion On New Drugs For Hepatitis CForbes Bloomberg –CNBC.com all 15 news articles |
Source: Business News From Google News
Zennie Abraham | Zennie Abraham or “Zennie62” is the founder of Zennie62Media which consists of zennie62blog.com and a multimedia blog news aggregator and video network, and 78-blog network, with social media and content development services and consulting. Zennie is a pioneer video blogger, YouTube Partner, social media practitioner, game developer, and pundit. Note: news aggregator content does not reflect the personal views of Mr. Abraham.